Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.62 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.62 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.62 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.62 |
| ▸ | ACE | P12821 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | FAP | Q12884 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30406108 | 1.00 | DPP4 (0.62) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL1136102 | 1.00 | DPP4 (0.62) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL1136099 | 1.00 | DPP4 (0.62) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL17001389 | 0.89 | DPP4 (0.59) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL18774237 | 0.87 | DPP4 (0.64) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL15166497 | 0.87 | DPP4 (0.57) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL15080519 | 0.87 | DPP4 (0.46) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL16750213 | 0.86 | DPP4 (0.56) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL13637938 | 0.86 | DPP4 (0.50) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL21497518 | 0.85 | DPP4 (0.55) | DPP4DPP8DPP7DPP9ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450315-B2 | Process for the preparation of dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor | LEE PHARMA LIMITED (IN) | 2019-10-22 | — | — | US | disclosed |
| US-20180265513-A1 | NOVEL PROCESS FOR THE PREPARATION OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ENZYME INHIBITOR | LEE PHARMA LIMITED (IN) | 2018-09-20 | — | — | US | disclosed |
| EP-3242879-A1 | NOVEL PROCESS FOR THE PREPARATION OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ENZYME INHIBITOR | Lee Pharma Ltd. (IN) | 2017-11-15 | — | — | EP | disclosed |
| WO-2016110750-A1 | NOVEL PROCESS FOR THE PREPARATION OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ENZYME INHIBITOR | LEE PHARMA LIMITED (IN) | 2016-07-14 | — | — | WO | disclosed |
| US-20140336196-A1 | PHOSPHORIC ACID SALTS OF SITAGLIPTIN | MERCK SHARP & DOHME CORP. (US) | 2014-11-13 | — | — | US | disclosed |
| EP-2547682-A1 | SOLID STATE FORMS OF SITAGLIPTIN SALTS | Teva Pharmaceutical Industries Ltd. (IL) | 2013-01-23 | — | — | EP | disclosed |
| US-20120316175-A1 | SOLID STATE FORMS OF SITAGLIPTIN SALTS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2012-12-13 | — | — | US | disclosed |
| US-8329696-B2 | Solid state forms of sitagliptin salts | TEVA PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2012-12-11 | — | — | US | disclosed |
| US-8278486-B2 | Process and intermediates for the preparation of N-acylated-4-aryl beta-amino acid derivatives | CHIRAL QUEST, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8183373-B2 | Solid state forms of sitagliptin salts | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2012-05-22 | — | — | US | disclosed |
| US-20090221595-A1 | Crystalline form of sitagliptin | TEVA PHARMACEUTICALS USA, INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090156579-A1 | Combination of a Dipeptidyl Peptidase-4 Inhibitor and an Anti-Hypertensive Agent for the Treatment of Diabetes and Hypertension | MERCK SHARP & DOHME CORP. | 2009-06-18 | — | — | US | disclosed |
| WO-2009070314-A2 | CRYSTALLINE FORM OF SITAGLIPTIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-06-04 | — | — | WO | disclosed |
| US-7495123-B2 | Process for the preparation of enantiomerically enriched beta amino acid derivatives | SOLVIAS AG (CH) | 2009-02-24 | — | — | US | disclosed |
| EP-1606243-B1 | PROCESS FOR THE PREAPAATION OF CHIRAL BETA AMINO ACID DERIVATIVES BY ASYMMETRIC HYDROGENATION | MERCK & CO INC (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20080058522-A1 | Process For The Preparation Of Enantiomerically Enriched Beta Amino Acid Derivatives | MERCK SHARP & DOHME LLC | 2008-03-06 | — | — | US | disclosed |
| US-7326708-B2 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | MERCK & CO., INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-20070281941-A1 | Amorphous Form of a Phosphoric Acid Salt of a Dipeptidyl Peptidase-IV Inhibitor | MERCK SHARP & DOHME LLC | 2007-12-06 | — | — | US | disclosed |
| EP-1654263-B1 | PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO INC (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20050032804-A1 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | MERCK SHARP & DOHME LLC | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221595-A1 | Crystalline form of sitagliptin | DPP4, DPP7, DPP9 | DPP4 1/4885DPP8 4/4885DPP7 2/4885 |
| US-20070281941-A1 | Amorphous Form of a Phosphoric Acid Salt of a Dipeptidyl Peptidase-IV Inhibitor | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 4/4885DPP7 2/4885 |
| US-20050032804-A1 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 4/4885DPP7 2/4885 |
| US-20140336196-A1 | PHOSPHORIC ACID SALTS OF SITAGLIPTIN | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 5/4885DPP7 2/4885 |
| US-20180265513-A1 | NOVEL PROCESS FOR THE PREPARATION OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ENZYME INHIBITOR | DPP4, DPP7, DPP9 | DPP4 1/4885DPP8 5/4885DPP7 2/4885 |
| US-20080058522-A1 | Process For The Preparation Of Enantiomerically Enriched Beta Amino Acid Derivatives | ATIC, SLC1A5, SLC7A1 | DPP4 980/4885DPP8 1505/4885DPP7 602/4885 |
| US-20090156579-A1 | Combination of a Dipeptidyl Peptidase-4 Inhibitor and an Anti-Hypertensive Agent for the Treatment of Diabetes and Hypertension | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 6/4885DPP7 2/4885 |
| US-20120316175-A1 | SOLID STATE FORMS OF SITAGLIPTIN SALTS | DPP4, DPP9, DPP7 | DPP4 1/4885DPP8 5/4885DPP7 3/4885 |
| US-10450315-B2 | Process for the preparation of dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 5/4885DPP7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.